Paul Schloesser – Endpoints News

SIGN UP

about the author

Paul Schloesser

Associate Editor

pschloesser@endpointsnews.com

Paul Schloesser on LinkedIn

Paul comes to Endpoints News as a recent graduate of the University of Missouri-Columbia, where he studied News Reporting and Political Science. Currently based in the Kansas City, Missouri area, his hobbies include cooking, doing escape rooms, and watching new TV shows. When not at his computer, he likes to check out new restaurants in his spare time.

author articles

Chinese cell therapy biotech developing TIL therapies raises $60M Series B

Last year

Verge Genomics teams up with AstraZeneca in drug discovery deal

Last year

Alnylam, Roche’s RNAi candidate scores mid-stage win in hypertension

Last year

CymaBay meets primary, key secondary endpoints in PhIII liver trial

Last year

iPSC biotech Shoreline Biosciences wins patent infringement suit over Fate, Whitehead Institute

Last year

Mersana CEO to step down after eight years; Royalty Pharma pays $150M for Skytrofa royalties

Last year

UK biotech brings in $226M Series C

Last year

Cancer drugs in US are ‘not affordable,’ says German study, which suggests setting drug prices by indication

Last year

CCM Biosciences breaks out of stealth with $25M; Two biotechs merge, to focus on Parkinson's

Last year

Bristol Myers secures FDA label expansion for anemia drug Reblozyl

Last year

Ginkgo teams up with Google Cloud; Two biotechs raise money through private placements

Last year

Alnylam plans to appeal Covid-19 vaccine patent ruling in case against Moderna

Last year

Novocure fails PhIII in platinum-resistant ovarian cancer

Last year

Novartis’ Leqvio cuts LDL levels by 50% over three years: #ESC23

Last year

Merck kick-starts PhIII cholesterol trials for its oral PCSK9; Baxter recalls 13,000+ vials of chemotherapy

Last year

CA federal judge allows former employee's case against SomaLogic to continue

Last year

Akebia expects to file vadadustat again to FDA by end of Q3; Societal CDMO seeks to secure 8M+ in latest raise

Last year

Mallinckrodt signs restructure agreement with creditors, plans to file for bankruptcy

Last year

Novartis to cut 103 clinical workers in New Jersey

Last year

Researchers suggest new methods to finance pediatric cancer R&D — Nature paper

Last year

Novavax says updated Covid-19 jab works against two subvariants; Ultimovacs revises PhII cancer vaccine readout

Last year

Inovio spinout plans pivotal study for cancer vaccine as it touts alternative take on PhIb/IIa liver cancer data

Last year

SpringWorks fixes 'minor data handling error' after March Form 483 for trial site linked to upcoming PDUFA

Last year

FDA OKs Ingrezza for treating chorea associated with Huntington’s; Abivax inks agreement for up to $163M in debt ...

Last year

12 3 4 Next page Last page